1. Carlino, MS, Long, GV. Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma? Clin Cancer Res 2016; 22: 3992–3998.
Google Scholar | Crossref | Medline2. Buchbinder, EI, Desai, A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39: 98–106.
Google Scholar | Crossref | Medline3. Seidel, JA, Otsuka, A, Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 2018; 8: 86.
Google Scholar | Crossref | Medline4. Zak, KM, Kitel, R, Przetocka, S, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 2015; 23: 2341–2348.
Google Scholar | Crossref | Medline5. Tarhini, AA . The current state of adjuvant therapy of melanoma. Lancet Oncol 2020; 21: 1394–1395.
Google Scholar | Crossref | Medline6. Correale, P, Rotundo, MS, Botta, C, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012; 18: 850–857.
Google Scholar | Crossref | Medline7. Indini, A, Di Guardo, L, Cimminiello, C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 2019; 145: 511–521.
Google Scholar | Crossref | Medline8. Eggermont, AMM, Kicinski, M, Blank, CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020; 6: 519–527.
Google Scholar | Crossref | Medline9. Eggermont, AMM, Chiarion-Sileni, V, Grob, J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845–1855.
Google Scholar | Crossref | Medline10. Eggermont, AMM, Chiarion-Sileni, V, Grob, JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–530.
Google Scholar | Crossref | Medline11. Ascierto, PA, Del Vecchio, M, Mandalá, M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21: 1465–1477.
Google Scholar | Crossref | Medline12. Eggermont, AMM, Blank, CU, Mandalà, M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22: 643–654.
Google Scholar | Crossref | Medline13. Eggermont, AMM, Blank, CU, Mandala, M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. Proc J Clin Oncol 2020; 38: 3925–3936.
Google Scholar | Crossref | Medline14. Eggermont, AM, Meshcheryakov, A, Atkinson, V, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. J Clin Oncol 2021; 158: 156–168.
Google Scholar | Crossref15. Boegeholz, J, Brueggen, CS, Pauli, C, et al. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. BMC Cancer 2020; 20: 300.
Google Scholar | Crossref | Medline16. Correale, P, Saladino, RE, Giannarelli, D, et al. HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis. Cells 2020; 9: 1964.
Google Scholar | Crossref | Medline17. Hasan Ali, O, Berner, F, Bomze, D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2019; 107: 8–14.
Google Scholar | Crossref | Medline18. Kramer, R, Zaremba, A, Moreira, A, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 2021; 147: 170–181.
Google Scholar | Crossref | Medline19. Vétizou, M, Pitt, JM, Daillère, R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079–1084.
Google Scholar | Crossref | Medline20. Freites-Martinez, A, Santana, N, Arias-Santiago, S, et al. Using the common terminology criteria for adverse events (CTCAE–Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 2021; 112: 90–92.
Google Scholar | Crossref | Medline21. Thompson, JA, Schneider, BJ, Brahmer, J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities version 1.2020. J Natl Compr Canc Netw 2020; 18: 230–241.
Google Scholar | Crossref | Medline22. Guo, Y, Lu, N, Bai, A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int 2013; 2013: 581631.
Google Scholar | Crossref | Medline23. Reinisch, W, Sandborn, WJ, Rutgeerts, P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 201–211.
Google Scholar | Crossref | Medline24. Johnson, DH, Zobniw, CM, Trinh, VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018; 6: 103.
Google Scholar | Crossref | Medline25. Wyant, T, Yang, L, Lirio, R, et al. P441 Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme). J Crohn’s Colitis 2019; 13: S331.
Google Scholar | Crossref26. Mancina, RM, Pagnotta, R, Pagliuso, C, et al. Gastrointestinal symptoms of and psychosocial changes in inflammatory bowel disease: a nursing-led cross-sectional study of patients in clinical remission. Med 2020; 56: 45.
Google Scholar27. Roberti, R, Iannone, LF, Palleria, C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020; 36: 1457–1463.
Google Scholar | Crossref | Medline28. Diana, P, Mankongpaisarnrung, C, Atkins, MB, et al. Emerging role of vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis. ACG Case Rep J 2018; 5: e17.
Google Scholar | Crossref | Medline29. Michielin, O, Van Akkooi, ACJ, Ascierto, PA, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884–1901.
Google Scholar | Crossref | Medline30. Rutgeerts, P, Sandborn, WJ, Feagan, BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
Google Scholar | Crossref | Medline31. Bergqvist, V, Hertervig, E, Gedeon, P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017; 66: 581–592.
Google Scholar | Crossref | Medline32. Abu-Sbeih, H, Ali, FS, Alsaadi, D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. J Immunother Cancer 2018; 6: 142.
Google Scholar | Crossref | Medline33. Abu-Sbeih, H, Ali, FS, Wang, X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019; 7: 93.
Google Scholar | Crossref | Medline34. Hsieh, AHC, Ferman, M, Brown, MP, et al. Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep 2016; 2016: bcr2016216641.
Google Scholar35. Scionti, F, Di Martino, MT, Sestito, S, et al. Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. Oncotarget 2017; 8: 107558–107564.
Google Scholar | Crossref | Medline36. Di Martino, MT, Scionti, F, Sestito, S, et al. Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget 2016; 7: 85895–85904.
Google Scholar | Crossref | Medline37. Arbitrio, M, Di Martino, MT, Scionti, F, et al. Pharmacogenomic profiling of ADME gene variants: current challenges and validation perspectives. High-Throughput 2018; 7: 40.
Google Scholar | Crossref38. Arbitrio, M, Scionti, F, Di Martino, MT, et al. Pharmacogenomics biomarker discovery and validation for translation in clinical practice. Clin Transl Sci 2021; 14: 113–119.
Google Scholar | Crossref | Medline